Share our mission of
improving patients’ lives.

Sutro’s Research and Development Collaborations allow our partners to leverage our drug discovery and development capabilities and our proprietary XpressCF® cell-free protein synthesis and XpressCF+® site-specific conjugation platforms

Research and Development Collaborations

In 2018, Sutro initiated a collaboration and licensing agreement with Merck Sharpe & Dohme, or Merck, known as MSD outside the United States and Canada, to discover and develop novel immune-modulating cytokine derivatives for for oncology and autoimmune indications.  Under the agreement, Sutro is primarily responsible for preclinical drug discovery and Merck holds exclusive worldwide development and commercialization rights to therapeutic candidates derived from the collaboration. Sutro is also responsible for manufacturing early-stage clinical supply using our XpressCF+® technology at our cGMP manufacturing facility.


In 2021, Sutro initiated a collaboration and licensing agreement with Tasly Biopharmaceuticals Co., Ltd. (hereinafter referred to as “Tasly”), a holding subsidiary of Tasly Pharmaceutical Group Co., Ltd. (SHA:600535) for the development and commercialization of STRO-002 in Greater China, consisting of mainland China, Hong Kong, Macau and Taiwan. STRO-002 is a FolRα-targeting antibody-drug conjugate (ADC), currently in clinical studies for patients with ovarian and endometrial cancers in the U.S. and Europe.


In 2022, Sutro Biopharma entered a worldwide, strategic collaboration and licensing agreement with Astellas focused on the discovery and development of novel immunostimulatory antibody-drug conjugates (iADCs). The collaboration leverages the unique cancer-fighting potential of iADCs as a novel modality, enabled by Sutro’s ability to engineer complex conjugated antibodies, and Astellas’ global oncology R&D expertise.



In 2024, Sutro Biopharma entered an exclusive global licensing agreement for STRO-003 with Ipsen. STRO-003, an antibody-drug conjugate (ADC) in the final stages of pre-clinical development, targets the ROR1 tumor antigen which is known to be overexpressed in many different cancer types including solid tumors and hematological malignancies. The agreement gives Ipsen exclusive worldwide rights to develop and commercialize STRO-003 and will be the first ADC candidate joining Ipsen’s expanding portfolio.